Development of systemically-deliverable oncolytic adenovirus

点击翻译按钮获取中文摘要

We previously established telomerase-specific oncolytic adenovirus (Telomelysin). Since the application of Telomelysin is basically restricted to local injection because of nonspecific capture in the liver and inactivation by immune system, we investigated the possibility of systemic delivery of Telomelysin by combining with one of the common nanomaterials, liposomes. TelomeScan, modified Telomelysin expressing green fluorescent protein (GFP), was alternatively used in this study. TelomeScan plasmid DNAs encapsulated by liposomes (Lipo-TelomeScan-pDNA) showed potent cytotoxic effects in vitro study against various types of cancer cells by yielding vigorous virus progenies. Especially, Lipo-TelomeScan-pDNA produced significantly strong cytotoxic activity against HCT-116, a human colon cancer cell line, compared to control plasmid DNA encapsulated by liposomes. In vivo examination is ongoing to evaluate the availability of Lipo-TelomeScan-pDNA for systemic delivery.